Download
1 / 16
160 likes | 349 Views
MIGSYS. Ian Evans, Genetics Max Musicant, SOM Grant Patterson, EPH Jia Kang, Med Informatics Colin Shaw, Nursing. YBPS Case Competition November 20, 2009. Patient Population Market Landscape. Biologics. Biologics. 5-ASAs. Steroids. Steroids. 5-ASAs. Immunomodulators.
E N D
MIGSYS Ian Evans, Genetics Max Musicant, SOM Grant Patterson, EPH Jia Kang, Med Informatics Colin Shaw, Nursing YBPS Case Competition November 20, 2009
Patient PopulationMarket Landscape Biologics Biologics 5-ASAs Steroids Steroids 5-ASAs Immunomodulators Immunomodulators
Target MarketDrug Usage By Disease Severity GTX-001 Biologic Disease Severity Mild Moderate Severe GTX-002 Immunomodulator Disease Severity Mild Moderate Severe
Opportunity 2: Science Behind GTX-001 Mechanism of Action: mAb against 11 integrin
Due Diligence • Released in 2004 for MS, Tysabri was then removed from market in 2005 due to cases of PML • Reintroduced in 2005 and since restricted to smaller patient segment • To date 24 cases of PML found in Tysabri users • GTX-001 is in the same class as Tysabri • mAb against a4-integrin • Decreases extravasation PML (Progressive Mulitfocal Leukoencephalopathy): a rare neurological disease
Recommendation: GTX-002 • Pros • A new class of kinase inhibitor • Cons • Existing market well served by many products • Low market prices for immunomodulators • Signs of side effects in pre-clinical studies • Financial models show inviability Recommendation: NO GO
Recommendation: GTX-001 • Pros • Large moderate and severe segments are underserved • Biologics command high prices in market • Large therapeutic window • Financial model shows significant profitability • Cons • Similar mechanism to existing treatment (Tysabri) • Significant medical risk associated with this class of molecules Recommendation: NO GO
Thank You from MIGSYS Ian Evans, Genetics Max Musicant, SOM Grant Patterson, EPH Jia Kang, Med Informatics Colin Shaw, Nursing
Tysabri, A Risky Proposition • Approved for the indication of CD in 2008 • Strong warnings not to use Tysabri with PML • in family history • Case Report: N Engl J Med 2005;353:362-8. • PML in patients who have received at least 24 infusions ranges from 0.4 to 1.3 per 1,000 in MS patients • CD patients make up only 2% of the Tysabri users • EMEA rejected Tysabri twice in 2007 Previous FDA Alert: [issued 2/2006] The FDA has lifted the clinical hold on Biogen-IDEC's trials of natalizumab for patients with multiple sclerosis (MS). Biogen-IDEC can now resume administration of natalizumab to patients with relapsing-remitting MS who had previously been treated with the drug in clinical trials. Biogen-IDEC had previously suspended marketing of natalizumab and all further dosing of patients in on-going clinical trials. This decision was made after confirmation of one fatal case and one additional case of severely disabling progressive multifocal leukoencephalopathy (PML) in patients receiving natalizumab for MS. A third case of PML, this one fatal, in a patient with Crohn's Disease had been identified shortly thereafter.
